Laura joined Myris Therapeutics as CEO in 2024, following her role as CEO of OncXerna Therapeutics and prior leadership roles at Eli Lilly and Harvard Medical School. She is an experienced cancer and vascular biology researcher who with a passion for improving patients’ lives through innovative drug discovery and development.
Recent Posts
- Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
- BioHybrid Solutions Holdings, Inc. Announces Expansion of its Drug Development Leadership
- BioHybrid Solutions Holdings, Inc. Appoints Mark Murcko as Board Member
- BioHybrid Solutions™ announces the formation of its Holdings Corporation and Subsidiaries
- BioHybrid Solutions™ Announces Jean Pineault as President and Chief Executive Officer
Recent Comments